Clinicians in primary care face a growing challenge with multidrug resistant uropathogens in community-acquired urinary tract infections (UTIs). Consequently, empirical treatment protocols require constant updates to reflect shifting resistance patterns. A recent multicenter study in Spain, conducted by the GEIAP-SEIMC group, provides critical data on the susceptibility of these difficult-to-treat organisms.

The Rise of Multidrug Resistant Uropathogens

Researchers analyzed thousands of urine samples to determine the prevalence of extended-spectrum β-lactamase (ESBL) and carbapenemase-producing strains. Notably, Escherichia coli and Klebsiella pneumoniae remained the most frequent culprits. Furthermore, the OXA-48 enzyme emerged as the most common carbapenemase among these isolates. This finding underscores the complexity of treating even common infections in a community setting.

The study revealed significant resistance to traditional first-line oral agents. For instance, both ESBL-producing E. coli and K. pneumoniae showed very low susceptibility to ciprofloxacin and cotrimoxazole. However, certain older antibiotics maintained impressive activity. Susceptibility rates for nitrofurantoin and fosfomycin in ESBL-producing E. coli reached 95.6% and 85.8%, respectively. Therefore, these agents remain robust options for managing lower UTIs in the era of high resistance.

Clinical Implications for Primary Care

The increasing prevalence of resistance limits empirical choices. While carbapenems and aminoglycosides showed high activity, their use in primary care is often restricted or impractical. Additionally, the study noted that 5.4% of Pseudomonas aeruginosa isolates were extremely drug-resistant. This highlights the urgent need for local antibiograms to guide clinical decisions. Physicians should prioritize narrow-spectrum agents like nitrofurantoin to preserve the efficacy of broader antibiotics.

Frequently Asked Questions

Which uropathogens are most likely to be multidrug-resistant?

In the GEIAP-SEIMC study, ESBL-producing Escherichia coli and Klebsiella pneumoniae were the most common multidrug-resistant uropathogens identified in primary care samples.

Are oral antibiotics still effective against ESBL-producing E. coli?

Yes, agents like nitrofurantoin and fosfomycin show high susceptibility rates (over 85%) for ESBL-producing E. coli, making them preferred choices for uncomplicated community-acquired UTIs.

What is the most common carbapenemase found in community UTIs?

The study identified OXA-48 as the most frequent carbapenemase among the isolates, emphasizing the spread of carbapenem resistance beyond hospital environments.

Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or a substitute for professional clinical judgment. Treatment decisions should be individualized based on the patient's condition and local resistance patterns. Refer to the latest local and national guidelines for clinical practice.

References

Riquelme-Bravo E et al. Antimicrobial susceptibility profile of multidrug-resistant uropathogens in community-acquired urinary tract infections in Spain: A multicenter GEIAP-SEIMC study. Enferm Infecc Microbiol Clin (Engl Ed). 2026 Jun 01. doi: undefined. PMID: 42224822.

Indian Council of Medical Research (ICMR). Treatment Guidelines for Antimicrobial Use in Common Syndromes 2019.

Infectious Diseases Society of America (IDSA). 2024 Guidance on the Treatment of Antimicrobial Resistant Gram-Negative Infections.